Microplate Dx are an award-winning spinout diagnostics company specialising in the development of novel solutions to tackle the major global health threat of antimicrobial resistance.
To address the issue of antimicrobial resistance, Microplate Dx have developed a point-of-care diagnostic platform which can rapidly assess antibiotic susceptibility, enabling clinicians to prescribe the optimum antibiotic for effective patient treatment.
Based in Glasgow, Microplate Dx’s mission is to improve the quality of life for patients by providing antimicrobial stewardship in a cost-effective manner, ensuring patients get the right antibiotic treatment in minutes and not 2+ days later as per the current gold standard treatment. Antimicrobial resistance (AMR) is a major threat to global public health (WHO), currently responsible for more than 1.27 million global deaths each year and could result in 10 million deaths annually by 2050, more than cancer and diabetes combined.
In 2023, SIS Ventures invested in a funding round with existing investors Deepbridge Capital LLP and the University of Strathclyde in addition to new investors Scottish Enterprise, and Boston-based life sciences investor Thairm Bio, in line with the company’s plans for US market entry.
The investment will enable Microplate Dx to use the funding to scale up manufacturing, conduct clinical trials, obtain regulatory approvals, and expand their marketing and sales efforts.
Microplate Dx secures £2.5m to develop rapid antibiotic testing technologyRead more about Microplate Dx secures £2.5m to develop rapid antibiotic testing technology
Microplate Dx aligns perfectly with SIS Ventures’ goal of investing in impact-led enterprises to help address society’s greatest challenges and needs. Through its mission of improving patient quality of life, impact is at the very core of the company’s DNA. We’re looking forward to helping Stuart and his team continue embedding this impact, alongside ESG, as the business grows. Arran Dewar, Executive Director, SIS Ventures.